Get started
Author

Araz Eivazi

Observed institution: Xencor (United States)
ORCID: 0009-0006-8468-253X
Observed ORCID: 0009-0006-8468-253X
OpenAlex ID: A5060094291
Engineered antibody Fc variants with enhanced effector function
2006 · Greg A. Lazar, Wei Dang, et al. · Proceedings of the National Academy of Sciences · 826
Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF Variants
2003 · Paul M. Steed, Malú G. Tansey, et al. · Science · 256
Dominant-Negative Inhibitors of Soluble TNF Attenuate Experimental Arthritis without Suppressing Innate Immunity to Infection
2007 · Jonathan Zalevsky, Thomas Secher, et al. · The Journal of Immunology · 160
A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens
2011 · Gregory L. Moore, Cristina Bautista, et al. · mAbs · 110
PDF
A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats
2018 · Gregory L. Moore, Matthew J. Bernett, et al. · Methods · 74
PDF
A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
2024 · Gregory L. Moore, Veronica G. Zeng, et al. · Molecular Cancer Therapeutics · 21
PDF
Abstract 1860: Bispecific claudin-6 x CD3 antibodies in a 2 + 1 format demonstrate selectivity and activity on human ovarian cancer cells
2021 · Matthew S. Faber, Sung-Hyung Lee, et al. · Cancer Research · 8
707 IL12 Fc-fusions engineered for reduced potency and extended half-life exhibit strong anti-tumor activity and improved therapeutic index compared to wild-type IL12 agents
2021 · Matthew Bernett, Ke Liu, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
CD2 x IL2RG bispecific antibodies synergistically modulate lymphocyte activation, resulting in suppression of inflammation and prevention of GVHD 2258985
2026 · Ke Liu, Michael Cadell, et al. · The Journal of Immunology
PDF
Figure 3 from A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
2025 · Gregory L. Moore, Veronica G. Zeng, et al.
Figure 4 from A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
2025 · Gregory L. Moore, Veronica G. Zeng, et al.
Figure 5 from A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
2025 · Gregory L. Moore, Veronica G. Zeng, et al.
Figure 1 from A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
2025 · Gregory L. Moore, Veronica G. Zeng, et al.
Figure 6 from A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
2025 · Gregory L. Moore, Veronica G. Zeng, et al.
Supplementary Figure S1 from A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
2025 · Gregory L. Moore, Veronica G. Zeng, et al.
Supplementary Figure S2 from A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
2025 · Gregory L. Moore, Veronica G. Zeng, et al.
Data from A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
2025 · Gregory L. Moore, Veronica G. Zeng, et al.
Figure 2 from A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
2025 · Gregory L. Moore, Veronica G. Zeng, et al.
Abstract 3515: Engineered IL18 heterodimeric Fc-fusions featuring improved stability, reduced potency, and insensitivity to IL18BP
2022 · Alex Nisthal, Sung-Hyung Lee, et al. · Cancer Research
Abstract 1743: IL12 heterodimeric Fc-fusions engineered for reduced potency exhibit strong anti-tumor activity and improved therapeutic index compared to native IL12 agents
2021 · Matthew J. Bernett, Ke Liu, et al. · Cancer Research
Works count: 20
Citation count: 1,456
H-index: 7
I10-index: 6
Year
Topic
Type